Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

New research finds that GLP-1 receptor agonist medications like Ozempic may help lower your Alzheimer's risk. What doctors ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

Unlike the Florida study, the Galway analysis did not find similar benefits for SGLT2 inhibitors or pioglitazone. These findings suggest that GLP-1 receptor agonists may have a more distinct role ...

Research shows diabetes medications may cut Alzheimer's risk by up to 43% in patients with type 2 diabetes, offering ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

These included GLP-1 receptor agonists like Ozempic (which promote insulin production and feelings of fullness); SGLT2 inhibitors (which prevent the kidneys from reabsorbing glucose, forcing its ...